Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a 30-Day habit shift help blood cancer patients regain control?

NCT ID NCT07674212

Disease control Sponsor: Jitka Vseteckova Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study tests a self-management program called Take5Care+ for adults recently diagnosed with slow-growing blood cancers. Participants choose a healthy habit—like better nutrition or more physical activity—and commit to it for 30 days. The goal is to see if this simple approach is feasible and helps patients feel more in control of their health and well-being.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Take5Care+ self-management program (healthy habit commitment for 30 days)
What this could lead to
If successful, this program could give blood cancer patients a simple, low-cost way to improve their well-being and sense of control after diagnosis.
What could go wrong
This is a very small feasibility study with only 20 participants, so results may not apply to everyone. The program relies on personal motivation, and long-term benefits are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years or older. * Have been diagnosed within the last 3 months with one of the eligible conditions listed in Table 1. * Be managed with either: * Active monitoring, or * Non-intensive oral therapy, defined as outpatient oral regimens that do not require inpatient initiation and have lower expected toxicity (e.g., BTK inhibitors, TKIs, interferon, lenalidomide, hydroxycarbamide, low-dose alkylators). * Have ECOG Performance Status 0-2. * Be able to give informed consent. * Be judged suitable for participation by the treating clinician. Exclusion Criteria: * Receiving intensive chemotherapy, immunotherapy, IV combination regimens, cellular therapy, radiotherapy or treatments requiring inpatient initiation. * Received or expected to require regular blood product transfusions * Life expectancy \<12 months. * Acutely terminal illness. * ECOG ≥3. * Cognitive impairment that would prevent the patient from giving informed consent, or reliably completing the daily action and follow-up assessments * Pregnant or lactating. * Currently participating in a CTIMP or other behavioural research intervention. * Age \<18. * Unstable, uncontrolled, or severe comorbidities: * Uncontrolled heart failure, unstable angina, or MI \<3 months. * Stroke/TIA \<3 months. * Severe/unstable COPD or asthma with recent exacerbations. * Poorly controlled diabetes * Severe psychiatric illness interfering with participation. * Concurrent active malignancy requiring systemic therapy. * Any other condition that, in the investigator's judgement, would compromise safe participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematologic neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematologic neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.